Imatinib(Marketed as Glivec in USA and Gleevec in Europe)is a tyrosine kinase inhibitor(TKI),commonly used as a first-line therapy for treatment of Gastrointestinal Stromal Tumors(GIST)and Chronic Myeloid Leukemia(CML).Although Imatinib application resulted in an impressive improvement in the survival of both GIST and CML patients,the response rate and the incidence of adverse reactions may considerably vary among single individuals.It is known that transporters are very important in the Imatinib absorption,distribution,metabolism,and excretion processes.To date,the role of efflux transporters has been explored extensively,however,the data about the effects of uptake transporters[solute carriers(SLC)]in Imatinib pharmacokinetics and pharmacodynamics are scarce and contradictory.This study,therefore,investigated the influence of genetic polymorphisms of SLC22A1,SLCO1A2and SLCO1B3on the adverse effects and pharmacokinetics of Imatinib in patients with GIST.
展开▼
